1.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GERN Giù?
Forum
Previsione
Precedente Chiudi:
$1.39
Aprire:
$1.38
Volume 24 ore:
8.18M
Relative Volume:
1.08
Capitalizzazione di mercato:
$868.16M
Reddito:
$29.48M
Utile/perdita netta:
$-201.19M
Rapporto P/E:
-4.25
EPS:
-0.32
Flusso di cassa netto:
$-216.50M
1 W Prestazione:
+3.82%
1M Prestazione:
+9.68%
6M Prestazione:
-12.82%
1 anno Prestazione:
-65.31%
Geron Corp Stock (GERN) Company Profile
Nome
Geron Corp
Settore
Industria
Telefono
(650) 473-7700
Indirizzo
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Confronta GERN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
GERN
Geron Corp
|
1.36 | 887.31M | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Sell |
| 2025-05-08 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-02-27 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2025-02-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Iniziato | Leerink Partners | Outperform |
| 2024-04-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-04-29 | Iniziato | TD Cowen | Buy |
| 2024-03-15 | Reiterato | Needham | Buy |
| 2023-09-12 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-28 | Iniziato | Goldman | Neutral |
| 2022-10-28 | Iniziato | Wedbush | Outperform |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2021-11-02 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Ripresa | B. Riley Securities | Buy |
| 2020-08-03 | Iniziato | Stifel | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-09-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-04-09 | Aggiornamento | Needham | Hold → Buy |
| 2019-01-31 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-10-02 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-07-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2016-09-13 | Reiterato | FBR & Co. | Outperform |
| 2016-09-13 | Reiterato | FBR Capital | Outperform |
| 2015-12-07 | Reiterato | Piper Jaffray | Overweight |
| 2015-04-21 | Iniziato | Oppenheimer | Outperform |
| 2014-06-12 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-03-12 | Downgrade | MLV & Co | Buy → Hold |
| 2013-12-10 | Reiterato | MLV & Co | Buy |
| 2013-12-10 | Aggiornamento | Needham | Hold → Buy |
| 2013-11-08 | Reiterato | MLV & Co | Buy |
| 2013-10-16 | Iniziato | MLV & Co | Buy |
| 2012-08-30 | Iniziato | Stifel Nicolaus | Buy |
| 2012-06-28 | Iniziato | Needham | Hold |
Mostra tutto
Geron Corp Borsa (GERN) Ultime notizie
Geron stock falls as H.C. Wainwright reiterates Neutral rating amid restructuring - Investing.com
Geron Corporation (NASDAQ:GERN) Nasdaq Composite ETF Clinical Trials - Kalkine Media
Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting - Yahoo Finance
Foster City drug maker Geron to lay off one-third of staff under new CEOSan Francisco Business Times - The Business Journals
Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On Sidelines (GERN) - Seeking Alpha
Geron Corporation (GERN) Announces Significant Workforce Reducti - GuruFocus
Geron (GERN) Initiates Strategic Restructuring for Long-Term Gro - GuruFocus
Geron to cut workforce by one-third in strategic restructuring - Investing.com
Geron Corporation Announces Strategic Restructuring to Enhance RYTELO® U.S. Commercial Strategy and Reduce Operating Expenses - Quiver Quantitative
Geron (Nasdaq: GERN) plans one-third cut as 2026 operating expenses expected below 2025 - Stock Titan
Geron stock rating reiterated as Neutral by H.C. Wainwright - Investing.com
Geron (GERN) Highlights Promising ASH 2025 Data on RYTELO - GuruFocus
Geron reports early cytopenia may signal response in MDS patients - Investing.com
Geron Corporation Presents New Data on Imetelstat at ASH 2025, Highlighting Clinical Benefits in Lower-Risk Myelodysplastic Syndromes and Myelofibrosis - Quiver Quantitative
Geron (Nasdaq: GERN) presents ASH 2025 RYTELO data on LR-MDS cytopenias, survival trends - Stock Titan
How Geron Corporation (GON) stock correlates with oil marketsWeekly Gains Report & Daily Profit Focused Screening - Newser
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - Benzinga
What consensus target says about Geron Corporation (GON) stockJuly 2025 EndofMonth & High Conviction Buy Zone Picks - Newser
Will Geron Corporation (GON) stock keep raising dividends2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
Why Geron Corporation (GON) stock stays on buy listsStop Loss & Daily Stock Trend Reports - Newser
Geron Corporation $GERN Stake Increased by Geode Capital Management LLC - MarketBeat
Geron Corporation (NASDAQ:GERN) is favoured by institutional owners who hold 64% of the company - Yahoo Finance
Wall Street Turns Bullish on Geron Corporation (GERN) amid Rytelo Sales Push Plans - Insider Monkey
10 Fastest Growing Penny Stocks to Buy Now - Insider Monkey
Geron Corporation (GERN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market reaction to Geron Corporation’s recent newsPortfolio Update Summary & Daily Stock Momentum Reports - newser.com
Will Geron Corporation stock gain from lower inflationWeekly Trend Recap & Weekly High Potential Alerts - newser.com
Will Geron Corporation (GON) stock extend growth storyWeekly Risk Report & Free AI Powered Buy and Sell Recommendations - newser.com
Why analysts maintain buy rating on Geron Corporation (GON) stockJuly 2025 Earnings & Reliable Entry Point Alerts - newser.com
Geron’s Survival Strategy Faces Critical Test - AD HOC NEWS
Will Geron Corporation stock rally after Fed decisions2025 Technical Overview & Fast Momentum Entry Tips - newser.com
Why Geron Corporation (GON) stock is trending on social mediaWeekly Stock Summary & Weekly Market Pulse Alerts - newser.com
Published on: 2025-11-19 19:45:31 - newser.com
Can Geron Corporation (GON) stock resist broad market declinesIPO Watch & Advanced Swing Trade Entry Plans - newser.com
Is Geron Corporation stock cheap at current valuationMarket Weekly Review & Target Return Focused Picks - newser.com
Published on: 2025-11-19 14:50:12 - newser.com
Published on: 2025-11-19 10:47:42 - newser.com
Why Geron Corporation (GON) stock remains stable2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Will Geron Corporation stock outperform growth indexesRate Hike & High Yield Equity Trading Tips - newser.com
Will Geron Corporation stock deliver strong dividend growth2025 Market Outlook & Verified Swing Trading Watchlist - newser.com
Geron Corporation (NASDAQ:GERN) Given Average Rating of "Hold" by Analysts - MarketBeat
Published on: 2025-11-16 22:14:00 - newser.com
What hedge fund activity signals for Geron Corporation stockJuly 2025 EndofMonth & Precise Entry and Exit Recommendations - newser.com
Why Geron Corporation stock remains on watchlistsTrade Volume Report & Verified Entry Point Signals - newser.com
Published on: 2025-11-14 23:47:36 - newser.com
How Geron Corporation stock performs in stagflationTrade Analysis Summary & Weekly Market Pulse Updates - newser.com
Geron Corp Azioni (GERN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Geron Corp Azioni (GERN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Samuels Scott Alan | EVP, Chief Legal Officer |
Feb 27 '25 |
Buy |
1.61 |
15,000 |
24,150 |
26,682 |
| SCARLETT JOHN A | Chairman, President and CEO |
Feb 27 '25 |
Buy |
1.76 |
12,500 |
22,062 |
12,500 |
| Ziegler James | EVP, Chief Commercial Officer |
Feb 27 '25 |
Buy |
1.60 |
100,000 |
160,000 |
100,000 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):